The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock ...

with protection observed against both RSV A and RSV B subtypes. Three vaccines are currently approved to prevent RSV-LRTD in people aged 60 years or older: an adjuvanted RSV prefusion F protein ...

Pregnant women's attitudes towards receiving the respiratory syncytial virus (RSV) vaccine to protect their newborn babies ...

One less infant, under the age of six months, was hospitalised each day following the release of the Respiratory Syncytial ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...